Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study

Key Points In patients with cancer with VTE and thrombocytopenia, modified-dose anticoagulation was associated with a lower rate of major hemorrhage. In this cohort, recurrent VTE was not observed after initiation of modified-dose anticoagulation.

[1]  G. Soff,et al.  The incidence of thrombocytopenia in adult patients receiving chemotherapy for solid tumors or hematologic malignancies , 2021, European journal of haematology.

[2]  A. Makatsariya,et al.  Challenging anticoagulation cases: Cancer-associated venous thromboembolism and chemotherapy-induced thrombocytopenia - A case-based review of clinical management. , 2021, Thrombosis research.

[3]  A. Torbicki,et al.  Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. , 2020, The New England journal of medicine.

[4]  F. Aung,et al.  Practice Patterns and Clinical Outcomes of Platelet Alloimmunization in a Comprehensive Cancer Center , 2019, Blood.

[5]  G. Raskob,et al.  Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism , 2019, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[6]  A. Khorana,et al.  Management of anticoagulation for cancer‐associated thrombosis in patients with thrombocytopenia: A systematic review , 2018, Research and practice in thrombosis and haemostasis.

[7]  A. Khorana,et al.  Management of cancer‐associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH , 2018, Journal of thrombosis and haemostasis : JTH.

[8]  G. Lyman,et al.  Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  A. Khorana,et al.  Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review , 2018 .

[10]  D. Garcia,et al.  Patients treated for acute VTE during periods of treatment-related thrombocytopenia have high rates of recurrent thrombosis and transfusion-related adverse outcomes , 2017, Journal of Thrombosis and Thrombolysis.

[11]  T. Shea,et al.  Analysis of anticoagulation strategies for venous thromboembolism during severe thrombocytopenia in patients with hematologic malignancies: a retrospective cohort , 2017, Leukemia & lymphoma.

[12]  J. Wills,et al.  Enoxaparin dose reduction for thrombocytopenia in patients with cancer: a quality assessment study , 2015, Journal of Thrombosis and Thrombolysis.

[13]  J. Armitage,et al.  Venous thromboembolism in patients with hematologic malignancy and thrombocytopenia , 2016, American journal of hematology.

[14]  P. Bijur,et al.  Generalizability and Effectiveness of Butterfly Phlebotomy in Reducing Hemolysis. , 2016, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[15]  Agnes Y. Y. Lee,et al.  Management and outcomes of cancer-associated venous thromboembolism in patients with concomitant thrombocytopenia: a retrospective cohort study , 2015, Annals of Hematology.

[16]  H. Liebman.  Thrombocytopenia in cancer patients. , 2014, Thrombosis research.

[17]  S. Braekkan,et al.  Epidemiology of cancer-associated venous thrombosis. , 2013, Blood.

[18]  S. Barni,et al.  Chemotherapy-associated thromboembolic risk in cancer outpatients and effect of nadroparin thromboprophylaxis: results of a retrospective analysis of the PROTECHT study , 2011, Journal of Translational Medicine.

[19]  G. Lyman,et al.  Thromboprophylaxis with low‐molecular‐weight heparin in medical patients with cancer , 2009, Cancer.

[20]  A. Khorana.  Cancer and thrombosis: implications of published guidelines for clinical practice. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Khorana,et al.  Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. , 2008, Archives of internal medicine.

[22]  J. Segal,et al.  The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. , 2008, Blood.

[23]  J. Wilmot.  The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease : Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients , 2007 .

[24]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[25]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .